Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

27.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 236
Open 27.24
Bid (Size) 26.00 (1)
Ask (Size) 30.98 (2)
Prev. Close 27.24
Today's Range 27.24 - 27.24
52wk Range 13.02 - 37.75
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Performance

YTD
+63.11%
+63.11%
1 Month
-13.30%
-13.30%
3 Month
+10.69%
+10.69%
6 Month
+71.86%
+71.86%
1 Year
+108.74%
+108.74%

More News

Read More
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
From Arcturus Therapeutics
Via Business Wire
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Arcturus Therapeutics Dropped on Tuesday
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Dynavax Technologies Stock Sees Renewed Technical Strength
Via Investor's Business Daily
3 Biotech Stocks to Buy Before the Breakout
Via InvestorPlace
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
Via Investor's Business Daily
3 Biotech Stocks for Getting Rich in 2023
Via InvestorPlace
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
Via Investor's Business Daily
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Abcam Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
Via Investor's Business Daily
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.